Shanghai Raas Revenue and Competitors

SHANGHAI,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Shanghai Raas's estimated annual revenue is currently $14.3M per year.(i)
  • Shanghai Raas's estimated revenue per employee is $251,000

Employee Data

  • Shanghai Raas has 57 Employees.(i)
  • Shanghai Raas grew their employee count by 0% last year.

Shanghai Raas's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.1M49-18%$10MN/A
#2
$30.4M12129%N/AN/A
#3
$139.8M913-3%$200KN/A
#4
$84.1M0N/A$1.2MN/A
#5
$43.4M17330%N/AN/A
#6
$64.5M25712%N/AN/A
#7
$64.3M20526%$129.6MN/A
#8
$19.6M78-7%N/AN/A
#9
$65.8M2627%N/AN/A
#10
$73.7M23520%$115.5MN/A
Add Company

What Is Shanghai Raas?

Shanghai Raas Blood Products is a medical device company based out of SHANGHAI. Shanghai Raas Blood Products representatives, don't miss out on opportunities to build relationships with members on LinkedIn. Claim your page, write a simple description, and share content to attract followers that can lead to new customers, brand fans, and future employees. Go here to get started: http://linkd.in/1DUpBvu

keywords:N/A

N/A

Total Funding

57

Number of Employees

$14.3M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Shanghai Raas News

2022-04-17 - Worldwide Plasma Derived Medicine Industry to 2028 ...

... CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc.,...

2022-04-17 - Tesla and other firms look to reopen Shanghai factories ...

Other companies that are preparing to reopen include biotechnology firm Shanghai Raas Blood Products and a unit of Shanghai Pharmaceuticals,...

2022-04-13 - Human Fibrinogen Market 2022 Industry Scenario – CSL ...

LFB Group; Shanghai RAAS Blood Products; Jiangxi Boya Bio-Pharmaceutical; Hualan Biological Engineering; Harbin Pacific Biopharmaceutical; GREEN...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.7M5814%$64M
#2
$6.8M584%N/A
#3
$13.2M6015%N/A
#4
$8M61-27%N/A
#5
$318.4M63-6%N/A